{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:11:02Z","timestamp":1760004662281,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.diagmicrobio.2020.115039","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:11:40Z","timestamp":1583986300000},"page":"115039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China"],"prefix":"10.1016","volume":"97","author":[{"given":"Cuicui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuihua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0005","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0010","unstructured":"CLSI (2017). Performance Standards for Antimicrobial Susceptibility Testing.27th ed.CLSI supplement M100.Wayne,PA:Clinical and Laboratory Standards Institute;2017."},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1345\/aph.1L473","article-title":"Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance","volume":"43","author":"Crandon","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0025","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13054-017-1769-z","article-title":"Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study","volume":"21","author":"De Pascale","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1592\/phco.27.3.333","article-title":"Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004","volume":"27","author":"DeRyke","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.31.9.1420","article-title":"Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients","volume":"31","author":"Drusano","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0055","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2011.04005.x","article-title":"Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal","volume":"72","author":"Garot","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0065","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.mayocp.2016.06.024","article-title":"A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae","volume":"91","author":"Gutierrez-Gutierrez","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0070","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2020.115039_bb0075","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cmi.2016.01.001","article-title":"Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014","volume":"22","author":"Hu","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0080","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.clinthera.2010.04.003","article-title":"Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States","volume":"32","author":"Koomanachai","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2016.03.020","article-title":"Application of Pharmacodynamic Profiling for the Selection of Optimal beta-lactam Regimens in a Large University Hospital","volume":"46","author":"Koomanachai","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0090","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0095","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/1469-0691.12144","article-title":"Incidence of bloodstream infection: a review of population-based studies","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0105","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.48.12.4718-4724.2004","article-title":"Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation","volume":"48","author":"Lodise","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diagmicrobio.2007.03.015","article-title":"Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae","volume":"58","author":"Lodise","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0115","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0120","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0125","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1128\/AAC.02747-15","article-title":"Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model","volume":"60","author":"Nicasio","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0130","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.amjmed.2007.01.035","article-title":"Sepsis","volume":"120","author":"O'Brien","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2010.10.024","article-title":"Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region","volume":"37","author":"Roberts","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0145","doi-asserted-by":"crossref","unstructured":"Rodriguez-Bano, J., Gutierrez-Gutierrez, B., Machuca, I., and Pascual, A. (2018). Treatment of Infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev 31.","DOI":"10.1128\/CMR.00079-17"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003088-200645050-00004","article-title":"Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients","volume":"45","author":"Simon","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coph.2017.09.009","article-title":"Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection","volume":"36","author":"Trang","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0160","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115039_bb0165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/40.2.269","article-title":"Intermittent bolus dosing of ceftazidime in critically ill patients","volume":"40","author":"Young","year":"1997","journal-title":"J Antimicrob Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320302455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320302455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:21Z","timestamp":1760003661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320302455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0732889320302455"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115039","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115039"}}